02585nam 2200601 a 450 991078100370332120230725051730.00-309-18648-X1-282-97591-997866129759120-309-14884-7(CKB)2550000000032080(SSID)ssj0000467759(PQKBManifestationID)11320034(PQKBTitleCode)TC0000467759(PQKBWorkID)10490553(PQKB)10059879(MiAaPQ)EBC3378727(Au-PeEL)EBL3378727(CaPaEBR)ebr10443269(CaONFJC)MIL297591(OCoLC)709768285(EXLCZ)99255000000003208020110215d2010 uy 0engurcn|||||||||txtccrCNS clinical trials[electronic resource] suicidality and data collection : workshop summary /Sarah Hanson, Miriam Davis, and Bruce Altevogt ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences PolicyWashington, D.C. National Academies Press2010xii, 75 pBibliographic Level Mode of Issuance: Monograph0-309-14883-9 Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration."The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description.SuicideRisk factorsSuicidePreventionSuicideRisk factors.SuicidePrevention.616.85/8445Hanson Sarah1530878Davis Miriam856948Altevogt Bruce M1478507Institute of Medicine (U.S.).Forum on Neuroscience and Nervous System Disorders.National Academies Press (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910781003703321CNS clinical trials3842899UNINA